Ironwood Pharmaceuticals, Inc. - Class A (IRWD) analyst actions
Rating and price-target actions on IRWD in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the IRWD overview →
8 measured IRWD analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients | Press release | -1.43% | -4.79% | |
| Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance | Press release | -0.37% | -10.90% | |
| Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook | Press release | -15.37% | -6.92% | |
| Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance | Press release | +6.75% | -6.97% | |
| Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance | Press release | +5.98% | -4.35% | |
| Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance | Press release | -8.01% | -4.84% | |
| Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future | Press release | -11.67% | -30.30% | |
| Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance | Press release | +1.65% | +5.37% |
Keep exploring
More IRWD: earnings → · SEC filings → · IRWD overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| REGENERX BIOPHARMS INC (RGRX) | 343 | 0.00% | 36% |
| Allena Pharmaceuticals, Inc. (ALNA) | 342 | 0.00% | 41% |
| Brookdale Senior Living Inc. (BKD) | 341 | +0.36% | 62% |
| Vaxart, Inc. (VXRT) | 341 | -0.81% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.